Fiscal Period | 2023 |
---|---|
Period End Date | Mar 23 |
Revenue | 10930.67 |
Total Revenue | 10930.67 |
Costof Revenue Total | 2250.22 |
Gross Profit | 8680.45 |
Selling/ General/ Admin Expenses Total | 2179.55 |
Depreciation/ Amortization | 671.53 |
Unusual Expense( Income) | 171.45 |
Other Operating Expenses Total | 3671.60 |
Total Operating Expense | 8944.35 |
Operating Income | 1986.32 |
Interest Inc( Exp) Net- Non- Op Total | -1199.10 |
Other Net | 373.28 |
Net Income Before Taxes | 2239.69 |
Provisionfor Income Taxes | 222.91 |
Net Income After Taxes | 2016.78 |
Minority Interest | 1.57 |
Equity In Affiliates | -338.80 |
Net Income Before Extra Items | 1984.47 |
Net Income | 1984.47 |
Income Availableto Com Excl Extra Ord | 1984.47 |
Income Availableto Com Incl Extra Ord | 1984.47 |
Diluted Net Income | 1984.47 |
Diluted Weighted Average Shares | 238.72 |
Diluted EPS Excluding Extra Ord Items | 8.31 |
DPS- Common Stock Primary Issue | 4.00 |
Diluted Normalized EPS | 8.96 |
Sun Pharmaceutical Industries Dividend | Sun Pharmaceutical Industries Bonus | Sun Pharmaceutical Industries News | Sun Pharmaceutical Industries AGM | Sun Pharmaceutical Industries Rights | Sun Pharmaceutical Industries Splits | Sun Pharmaceutical Industries Board Meetings | Sun Pharmaceutical Industries Key Metrics | Sun Pharmaceutical Industries Shareholdings | Sun Pharmaceutical Industries Profit Loss | Sun Pharmaceutical Industries Balance Sheet | Sun Pharmaceutical Industries Cashflow | Sun Pharmaceutical Industries Q1 Results | Sun Pharmaceutical Industries Q2 Results | Sun Pharmaceutical Industries Q3 Results
Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks